-+ 0.00%
-+ 0.00%
-+ 0.00%

Medivir Wins Rare Pediatric Disease Designation for MIV-711

MT Newswires·11/19/2026 04:07:50
Listen to the news
04:07 AM EST, 11/19/2026 (MT Newswires) -- The US Food and Drug Administration gave Medivir's (MVIR.ST) MIV-711 a rare pediatric disease designation to treat patients with osteogenesis imperfecta. The pharmaceutical company said Thursday that the new designation was secured after meeting the US FDA's criteria to classify osteogenesis imperfecta as a rare pediatric disease. Medivir can potentially secure a priority review voucher for a future US FDA marketing application for the selective cathepsin K inhibitor.